1. Articles in category: Information

    1-24 of 340 1 2 3 4 ... 13 14 15 »
    1. Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Biol Direct. 2018 Jul 16;13(1):14

      Authors: Suo C, Deng W, Vu TN, Li M, Shi L, Pawitan Y

      Abstract BACKGROUND: Neuroblastoma is the most common pediatric malignancy with heterogeneous clinical behaviors, ranging from spontaneous regression to aggressive progression.

      Read Full Article
      Mentions: MYCN
    2. Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Asia Ocean J Nucl Med Biol. 2018;6(2):161-166

      Authors: Araki R, Nishimura R, Inaki A, Wakabayashi H, Imai Y, Kuribayashi Y, Yoshimura K, Murayama T, Kinuya S

      Read Full Article
      Mentions: MIBG Chemotherapy
    3. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Br J Cancer. 2018 Jul 11;:

      Authors: Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T

      Read Full Article
      Mentions: GPOH Chemotherapy
    4. EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat children with high-risk neuroblastoma within the NHS in England and Wales.i High-risk neuroblastoma is an aggressive form of neuroblastoma – the most common solid tumour of childhood that originates outside of the brain.ii Dinutuximab beta is the first targe

      Read Full Article
    5. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      Front Immunol. 2018;9:1355

      Authors: Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL

      Read Full Article
      Mentions: Antibody COG
    6. A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

      A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy

      Novel druggable targets have been discovered in neuroblastoma (NB), paving the way for more effective treatments. However, children with high-risk NB still show high mortality rates prompting for a search of novel therapeutic options. Here, we aimed at repurposing FDA-approved drugs for NB treatment by performing a high-content screening of a 349 anticancer compounds library.

      Read Full Article
      Mentions: Treatment
    7. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma.

      ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma.

      Proc Natl Acad Sci U S A. 2018 Jun 25;:

      Authors: Pieraccioli M, Nicolai S, Pitolli C, Agostini M, Antonov A, Malewicz M, Knight RA, Raschellà G, Melino G

      Abstract Derangement of cellular differentiation because of mutation or inappropriate expression of specific genes is a common feature in tumors.

      Read Full Article
      Mentions: MYCN
    8. Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma.

      Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma.

      J Clin Invest. 2018 Jun 25;:

      Authors: Hassannia B, Wiernicki B, Ingold I, Qu F, Van Herck S, Tyurina YY, Bayır H, Abhari BA, Angeli JPF, Choi SM, Meul E, Heyninck K, Declerck K, Chirumamilla CS, Lahtela-Kakkonen M, Van Camp G, Krysko DV, Ekert PG, Fulda S, De Geest BG, Conrad M, Kagan VE, Berghe WV, Vandenabeele P, Berghe TV

      Read Full Article
    9. LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

      LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

      Clin Cancer Res. 2018 Jun 20;:

      Authors: Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, De Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C

      Read Full Article
      Mentions: MYCN LDH
    10. Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Int J Cancer. 2018 Jun 21;:

      Authors: Norsker FN, Rechnitzer C, Cederkvist L, Tryggvadottir L, Madanat-Harjuoja LM, Øra I, Thorarinsdottir HK, Vettenranta K, Bautz A, Schrøder H, Hasle H, Winther JF

      Read Full Article
    11. Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      J Adv Pract Oncol. 2017 Jan-Feb;8(1):44-55

      Authors: Armideo E, Callahan C, Madonia L

      Abstract Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials.

      Read Full Article
    12. Lymph microvascularization as a prognostic indicator in neuroblastoma.

      Lymph microvascularization as a prognostic indicator in neuroblastoma.

      Oncotarget. 2018 May 25;9(40):26157-26170

      Authors: Tadeo I, Gamero-Sandemetrio E, Berbegall AP, Gironella M, Ritort F, Cañete A, Bueno G, Navarro S, Noguera R

      Abstract Neuroblastoma is the most common extra-cranial solid pediatric cancer and causes approximately 15% of all childhood deaths from cancer.

      Read Full Article
    13. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Cancer. 2018 Jun 11;:

      Authors: Zheng DJ, Krull KR, Chen Y, Diller L, Yasui Y, Leisenring W, Brouwers P, Howell R, Lai JS, Balsamo L, Oeffinger KC, Robison LL, Armstrong GT, Kadan-Lottick NS

      Read Full Article
    14. Children with neuroblastoma have an elevated risk of long-term psychological difficulties

      A new study reveals that paediatric neuroblastoma patients are at elevated risk for long-term psychological impairment.

      In addition, those who experience such impairment as they get older tend to require special education services and to not go on to...

      Read Full Article
      Mentions: Treatment
    15. Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis.

      Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis.

      Cancer Manag Res. 2018;10:1359-1364

      Authors: Yin Z, Wang Y, Wu Y, Zhang X, Wang F, Wang P, Tao Z, Yuan Z

      Abstract Objective: The objective of the study was to describe the age distribution and to evaluate the role of prognostic value of age on survival in patients diagnosed with olfactory neuroblastoma (ONB). A population-based retrospective analysis was conducted.

      Read Full Article
    16. Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children.

      Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children.

      Mol Ther Nucleic Acids. 2018 Jun 01;11:1-8

      Authors: He J, Zou Y, Liu X, Zhu J, Zhang J, Zhang R, Yang T, Xia H

      Abstract Neuroblastoma is a commonly occurring extracranial pediatric solid tumor without defined etiology. Polymorphisms in pre-miRNAs have been demonstrated to associate with the risk of several cancers.

      Read Full Article
    17. A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.

      A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.

      Am J Surg Pathol. 2018 May 22;:

      Authors: Xie Y, Xu H, Fang F, Li Z, Zhou H, Pan J, Guo W, Zhu X, Wang J, Wu Y

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in children with contrasting outcomes. Precise risk assessment contributes to prognosis prediction, which is critical for treatment strategy decisions.

      Read Full Article
      Mentions: Treatment
    1-24 of 340 1 2 3 4 ... 13 14 15 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Organizations in the News

    1. (1 articles) SIOPEN
    2. (1 articles) COG
    3. (1 articles) GPOH
  4. Researches in the News

    1. (4 articles) MYCN
    2. (1 articles) Antibody
    3. (1 articles) Immunotherapy
    4. (1 articles) LDH
    5. (1 articles) Vaccine
  5. General Informations in the News

    1. (1 articles) Treatment
  6. Treatments in the News

    1. (2 articles) Chemotherapy
    2. (1 articles) MIBG
    3. (1 articles) Surgery